Odomzo Capsule
NDC Package 47335-303-83
Package Information
Odomzo (sonidegib) capsules is a medication used to treat a certain type of skin cancer (basal cell carcinoma). This formulation utilizes a capsule delivery system. Marketed by Sun Pharmaceutical Industries, Inc., this product is identified by NDC 47335-303 and is authorized under FDA application NDA205266.
Identification & Billing
- RxCUI: 1659921 - sonidegib 200 MG Oral Capsule
- RxCUI: 1659921 - sonidegib 200 MG (as sonidegib phosphate) Oral Capsule
- RxCUI: 1659927 - Odomzo 200 MG Oral Capsule
- RxCUI: 1659927 - sonidegib 200 MG Oral Capsule [Odomzo]
- RxCUI: 1659927 - Odomzo 200 MG (as sonidegib phosphate) Oral Capsule
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 47335 - Sun Pharmaceutical Industries, Inc.
- 47335-303 - Odomzo
- 47335-303-83 - 30 CAPSULE in 1 BOTTLE
- 47335-303 - Odomzo
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (47335-303). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 47335-303-83 identifies a specific commercial package of 30 capsule in 1 bottle of Odomzo, a human prescription drug labeled by Sun Pharmaceutical Industries, Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 30 billable units per package. This capsule is formulated for oral use and contains sonidegib phosphate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Sun Pharmaceutical Industries, Inc. on September 21, 2017. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
This medication is used to treat a certain type of skin cancer (basal cell carcinoma).
How is this Sun Pharmaceutical Industries, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 47335030383. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 30 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.